Larazotide: Zonulin Antagonist Studied in Celiac Disease

What is larazotide?

Larazotide is a synthetic 8-amino-acid peptide that regulates the tight junctions between cells lining the gut, studied mainly in celiac disease.

The intestinal lining is a single layer of cells held together by protein complexes called tight junctions. These junctions decide what passes between cells and what stays out (Slifer and Blikslager, 2020, PMID 33881350). Larazotide acetate was designed to keep those junctions closed when they would otherwise loosen (Khaleghi et al., 2016). Unlike most peptides discussed on this site, it is not meant to enter circulation. It is minimally absorbed and acts locally at the surface of the gut lining, which is why researchers describe it as a gut-restricted or luminally acting agent (Khaleghi et al., 2016; Leffler et al., 2015, PMID 25683116).

How does larazotide work on the gut barrier?

It acts as a zonulin antagonist, blocking the signaling that pulls tight junctions apart and increases intestinal permeability.

Zonulin is a protein that, when released, triggers the disassembly of tight junctions and raises paracellular permeability, the leak between cells (Slifer and Blikslager, 2020). In celiac disease, exposure to gluten fragments can drive zonulin release, loosen the junctions, and let more antigen reach the immune system underneath (Khaleghi et al., 2016). Larazotide is thought to interrupt this loop, promoting tight-junction reassembly and reducing the movement of antigens across the barrier (Khaleghi et al., 2016). The proposed result is a more stable barrier at the cellular level, which is the mechanism researchers were testing, not a proven clinical outcome.

Has larazotide been tested in humans?

Yes: it advanced through early and mid-stage trials and into phase 3 for celiac disease, but the phase 3 program was discontinued after a planned interim analysis.

Larazotide is the furthest-developed tight-junction regulator of its kind, and reviews describe its path through clinical testing as an add-on to a gluten-free diet in celiac disease (Khaleghi et al., 2016). The mid-stage evidence base includes a randomized, double-blind, placebo-controlled phase 2b study in adults with celiac disease and persistent symptoms despite a gluten-free diet, in which the 0.5 mg dose reduced symptoms more than placebo (Leffler et al., 2015). Despite that progress, the sponsor reported that the pivotal phase 3 study did not clear its planned interim futility analysis and the program was stopped (9 Meters Biopharma, 2022). As a result, larazotide has no approved indication, and it remains a research compound rather than a therapy. Human data outside celiac disease is limited.

What doses of larazotide were studied in research?

In the phase 2b trial, participants received low-milligram oral doses (0.5, 1, or 2 mg) three times daily before meals; this is what research reported, not a recommendation.

The table below reflects the dosing framework described in the primary trial and supporting review. It is here for context only. It is not a protocol. Any personal decision about a research compound belongs with a qualified clinician.

PL does not provide dosing instructions. The figures above describe how the compound was used in named research, and nothing here tells any reader what to take.

What side effects were reported with larazotide?

Reported adverse events were generally mild, and the most common complaints were gastrointestinal, consistent with a locally acting, poorly absorbed peptide.

In the phase 2b trial, adverse events were generally mild and larazotide was well tolerated, with gastrointestinal complaints among the reported effects (Leffler et al., 2015). Because larazotide is designed to stay in the gut lumen and is minimally absorbed, systemic exposure is low, which is reflected in its reported tolerability profile (Khaleghi et al., 2016). This does not establish benefit, and the phase 3 effort was later halted after an interim futility analysis (9 Meters Biopharma, 2022). No efficacy or safety claim should be read into these summaries beyond what the authors and the sponsor state.

How is larazotide different from other gut peptides?

Its distinguishing feature is where it works: at the tight junction, from inside the gut, rather than through the bloodstream like most peptides.

Many peptides covered on this site are absorbed and act on distant tissues. Larazotide is the opposite case. Its mechanism is confined to the intestinal barrier, which shapes both how it was dosed and how its safety reads (Khaleghi et al., 2016). If you are comparing gut-directed research peptides, note that larazotide is compound-specific and single-mechanism, defined entirely by its role as a zonulin antagonist and tight-junction regulator (Slifer and Blikslager, 2020; Khaleghi et al., 2016).